David A. Siegel Replimune Group, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Replimune Group, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,600 shares of REPL stock, worth $181,692. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,600
Previous 170,400
88.5%
Holding current value
$181,692
Previous $2.06 Million
90.74%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding REPL
# of Institutions
172Shares Held
78.5MCall Options Held
69.4KPut Options Held
216K-
Baker Bros. Advisors LP New York, NY11MShares$102 Million1.28% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$101 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA4.9MShares$45.4 Million5.02% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$43.7 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.91MShares$36.2 Million9.21% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $457M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...